Update on toll-like receptor-directed therapies for human disease

Annals of the Rheumatic Diseases

Volumn 66, Issue SUPPL. 3, 2007, Pages

  Tse, Kevin ^b   Horner, Anthony A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b San Diego   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; E 5564; HEPATITIS B VACCINE; IMIQUIMOD; IMMUNOMODULATING AGENT; LIPOPOLYSACCHARIDE; MELANOMA VACCINE; PHOSPHORYL LIPID A; PLATINUM; TAK 242; TAXANE DERIVATIVE; TOLAMBA; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3 AGONIST; TOLL LIKE RECEPTOR 4 AGONIST; TOLL LIKE RECEPTOR 4 ANTAGONIST; TOLL LIKE RECEPTOR 5 AGONIST; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR 9 AGONIST; TOLL LIKE RECEPTOR 9 ANTAGONIST; UNCLASSIFIED DRUG;

ALLERGY; AUTOIMMUNE DISEASE; CANCER; CANCER IMMUNIZATION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENDOTOXEMIA; HUMAN; IMMUNOSTIMULATION; IMMUNOTHERAPY; INFECTION; INNATE IMMUNITY; LUNG NON SMALL CELL CANCER; MELANOMA; MICROORGANISM; MONOTHERAPY; PRIORITY JOURNAL; PSORIASIS; UNSPECIFIED SIDE EFFECT; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; AUTOIMMUNE DISEASES; COMMUNICABLE DISEASES; HUMANS; HYPERSENSITIVITY; IMMUNITY, NATURAL; IMMUNOTHERAPY; LIGANDS; NEOPLASMS; SEPSIS; TOLL-LIKE RECEPTORS;

EID: 35648930568     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.078998     Document Type: Conference Paper

References (58)

1. Medzhitov R, Janeway Jr CA. Decoding the patterns of self and nonself by the innate immune system. Science 2002;296:298-300.
2. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783-801.
3. Hoebe K, Janssen E, Beutler B. The interface between innate and adaptive immunity. Nat Immunol 2004;5:971-4.
4. Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak-Rothstein A. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 2005;204:27-42.
5. Ishii KJ, Akira S. Innate immune recognition of nucleic acids: beyond toll-like receptors. Int J Cancer 2005;117:517-23.
6. Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol 2006;311:17-58.
7. Moynagh PN. TLR signalling and activation of IRFs: revisiting old friends from the NF-kappaB pathway. Trends Immunol 2005;26:469-76.
8. Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Adv Exp Med Biol 2005;560:11-8.
9. Chisholm D, Libet L, Hayashi T, Horner AA. Airway peptidoglycan and immunostimulatory DNA exposures have divergent effects on the development of airway allergen hypersensitivities. J Allergy Clin Immunol 2004;113:448-54.
10. Eisenbarth SC, Piggott DA, Huleatt JW, Visintin I, Herrick CA, Bottomly K. Lipopolysacchariae-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J Exp Med 2002;196: 1645-51.
11. Horner AA, Ronaghy A, Cheng PM, Nguyen MD, Cho HJ, Broide D, et al. Immunostimulatory DNA is a potent mucosal adjuvant. Cellular Immunology 1998;190:77-82.
12. Horner AA, Datta SK, Takabayashi K, Belyakov IM, Hayashi T, Cinman N, et al. Immunostimulatory DNA-basea vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites. J Immunol 2001;167:1584-91.
13. van Duin D, Medzhitov R, Shaw AC. Triggering TLR signaling in vaccination. Trends Immunol 2006;27:49-55.
14. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006;5:471-84.
15. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007;13:552-9.
16. Baldridge JR, McGowan P, Evans JT, Cluff C, Mossman S, Johnson D, et al. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther 2004;4:1129-38.
17. Dupont J, Altclas J, Lepetic A, Lombardo M, Vazquez V, Salgueira C, et al. A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine. Vaccine 2006;24:7167-74.
18. Halperin SA, Van Nest G, Smith B, Abtahi S, Whiley H, Eiden JJ. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 2003;21:2461-7.
19. Halperin SA, Dobson S, McNeil S, Langley JM, Smith B, McCall-Sani R, et al. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine 2006;24:20-6.
20. Wills-Karp M, Santeliz J, Karp CL. The germless theory of allergic diseases: revisiting the hygiene hypothesis. Nature Reviews, Immunology 2001;1:69-75.
21. Liu AH, Murphy JR. Hygiene hypothesis: fact or fiction? J Allergy Clin Immunol 2003;111:471-8.
22. Matricardi PM, Rosmini F, Panetta V, Ferrigno L, Bonini S. Hay fever and asthma in relation to markers of infection in the United States. J Allergy Clin Immunol 2002;110:381-7.
23. Horner AA. Toll-like receptor ligands and atopy: a coin with at least two sides. J Allergy Clin Immunol 2006;117:1133-40.
24. Sur S, Wild JS, Choudhury BK, Sur N, Alam R, Klinman DM. Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J Immunol 1999;162:6284-93.
25. Takabayashi K, Libet L, Chisholm D, Zubeldia J, Horner AA. Intranasal immunotherapy is more effective than intradermal immunotherapy for the induction of airway allergen tolerance in th2-sensitized mice. J Immunol 2003;170:3898-905.
26. Horner AA. Update on toll-like receptor ligands and allergy: implications for immunotherapy. Curr Allergy Asthma Rep 2006;6:395-401.
27. Braun-Fahrlander C, Riedler J, Herz U, Eder W, Waser M, Grize L, et al. Environmental exposure to endotoxin and its relation to asthma in school-age children. N Engl J Med 2002;347:869-77.
28. Gereda JE, Klinnert MD, Price MR, Leung DY, Liu AH. Metropolitan home living conditions associated with indoor endotoxin levels. J Allergy Clin Immunol 2001;107:790-6.
29. Patel P, Salapatek AM. Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine. Expert Rev Vaccines 2006;5:617-29.
30. Jutek M, Bachert C. Ultra-short-course seasonal allergy vaccine (Pollinex Quattro): viewpoints. Drugs 2006;66:939-40.
31. McCormack PL, Wagstaff AJ. Ultra-short-course seasonal allergy vaccine (Pollinex Quattro). Drugs 2006;66:931-8.
32. Horner AA, Takabayashi K, Beck L, Sharma B, Zubeldia J, Baird S, et al. Optimized conjugation ratios lead to allergen immunostimulatory oligodeoxynucleotide conjugates with retained immunogenicity and minimal anaphylactogenicity. J Allergy Clin Immunol 2002;110:413-20.
33. Tighe H, Takabayashi K, Schwartz D, Van Nest G, Tuck S, Eiden JJ, et al. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 2000;106:124-34.
34. Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006;355:1445-55.
35. Tulic MK, Fiset PO, Christodoulopoulos P, Vaillancourt P, Desrosiers M, Lavigne F, et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol 2004;113:235-41.
36. Creticos PS. Immunotherapy. In: Kaplan AP, eds. Allergy, 2nd edn. Philadelphia: Saunders, 1997:726-39.
37. Wang HY, Wang RF. Regulatory T cells and cancer. Curr Opin Immunol 2007;19:217-23.
38. Horna P, Sotomayor EM. Cellular and molecular mechanisms of tumor-induced T-cell tolerance. Curr Cancer Drug Targets 2007;7:41-53.
39. Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets 2007;7:31-40.
40. Spaner DE, Masellis A. Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia. Leukemia 2007;21:53-60.
41. Schon M, Schon MP. The antitumoral mode of action of imiquimod and other imidazoquinolines. Curr Med Chem 2007;14:681-7.
42. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007;117:1184-94.
43. Speiser DE, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005;115:739-46.
44. Witt PL, Ritch PS, Reding D, McAuliffe TL, Westrick L, Grossberg SE, et al. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer Res 1993;53:5176-80.
45. Del Rosso JQ. The treatment of viral infections and nonmelanoma skin cancers. Cutis 2007;79:29-35.
46. Chang YC, Madkan V, Cook-Norris R, Sra K, Tyring S. Current and potential uses of imiquimod. South Med J 2005;98:914-20.
47. Woodmansee C, Pillow J, Skinner Jr RB. The role of topical immune response modifiers in skin cancer. Drugs 2006;66:1657-64.
48. Friedberg JW, Kim H, McCauley M, Hessel EM, Sims P, Fisher DC, et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 2005;105:489-95.
49. Mason KA, Neal R, Hunter N, Ariga H, Ang K, Milas L. CpG oligodeoxynucleotides are potent enhancers of radio- and chemoresponses of murine tumors. Radiother Oncol 2006;80:192-8.
50. Gilliet M, Conrad C, Geiges M, Cozzio A, Thurlimann W, Burg G, et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol 2004;140:1490-5.
51. Wagner H. Endogenous TLR ligands and autoimmunity. Adv Immunol 2006;91:159-73.
52. Brentano F, Schorr O, Gay RE, Gay S, Kyburz D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum 2005;52:2656-65.
53. Lenert PS. Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus. Arthritis Res Ther 2006;8:203.
54. Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Aim G, Vallin H, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000;9:664-71.
55. Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005;202:1131-9.
56. Hawkins LD, Christ WJ, Rossignol DP. Inhibition of endotoxin response by synthetic TLR4 antagonists. Curr Top Med Chem 2004;4:1147-71.
57. Mullarkey M, Rose JR, Bristol J, Kawata T, Kimura A, Kobayashi S, et al. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther 2003;304:1093-102.
58. Lynn M, Rossignol DP, Wheeler JL, Kao RJ, Perdomo CA, Noveck R, et al. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis 2003;187:631-9.